Accuray Initiates International Commercial Launch of the InCise™ Multileaf Collimator for the CyberKnife® M6™ System

- Evaluation of the InCise™ Multileaf Collimator System Successfully Completed

SUNNYVALE, California, April 21, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the InCise™ Multileaf Collimator (MLC) for the CyberKnife® M6™ System will now be available outside the United States in markets where it is approved for sale, in addition to the U.S. market where the InCise MLC was commercially launched in February 2015. The launch follows the successful completion of the evaluation of the InCise MLC by Erasmus MC Cancer Institute in Rotterdam, the Netherlands, the European evaluation site working in collaboration with Accuray. Two sites in the U.S. had previously completed their successful evaluation of the InCise MLC. The main benefits of the MLC reported by the sites were the ability to treat a broader range of tumors than they could with fixed collimators or the Iris™ Collimator, and to do so with significantly increased efficiency. The InCise MLC will be featured at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting in Barcelona, Spain, April 24 – 27, 2015.

"We are continuing to advance our successful CyberKnife M6 System platform, through the introduction of the InCise MLC. The addition of the InCise MLC enhances the M6 system's functionality by significantly reducing treatment times and expands its versatility by broadening the range of patients and tumors that can be treated," said Joshua H. Levine, president and chief executive officer of Accuray. "We believe the M6, with the MLC, will enable clinicians to treat tumors they may have thought to be untreatable with SBRT, efficiently and with precise dose delivery."

The InCise MLC is the world's first multileaf collimator to be available on a robotic platform, the CyberKnife M6 System. The system's robotic design enables physicians to find the best angles for radiation to enter and exit the body, thus maximizing dose to the target while minimizing exposure to healthy tissue. The robotic design also enables the system to adjust and automatically stay on target in real-time, accounting for patient and tumor motion. The CyberKnife M6 System can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, non-surgical option.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to advantages of new technology, clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the market's failure to adopt our new product offerings and the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.